The correlation between circulating growth differentiation factor 11 and the risk of osteopenia/osteoporosis in men.

Abstract

Male osteopenia/osteoporosis remains a neglected subject or is under- or misdiagnosed. Many studies have confirmed the role of growth differentiation factor 11 (GDF11) in bone metabolism, although its role in bone metabolism remains controversial. In this study, we aimed to investigate the association between serum GDF11 levels and the prevalence of osteopenia/osteoporosis (OP) in a male cohort and explore the possibility of GDF11 to be a useful target for prediction of osteopenia/osteoporosis to enable prompt intervention for this disease. This cross-sectional study included 121 native Chinese men randomly aged 20-87 years, excluded the subjects who had the conditions of bone metabolism-related disease and administration of hormonal drugs, and grouped the subjects to OP and non-OP, based on the WHO definition and latest guidelines of OP. The serum GDF11 concentration was determined using a GDF11-specific immunoassay. Bone mineral density (BMD) was measured using dual-energy X-ray absorptiometry. Tartrate-resistant acid phosphatase 5b (TRAP-5b) were measured in serum samples with ELISA method. We observed a negative correlation between serum GDF11 levels and age, a positive correlation between serum GDF11 levels and the femoral neck BMD, and a negative correlation between serum GDF11 levels and TRAP-5b in men. The prevalence and risk of OP were significantly higher in men with low serum GDF11 levels. The serum GDF11 concentration is significantly associated with the risk of bone metabolism dysfunction and may be a useful target for prediction of OP in male cohort.